<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        20-349-11
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2011
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        RAMIPRIL SANDOZ 5MG TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        RAMIPRIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        23.4
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="LEK S.A" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            LEK S.A
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            HEXAL
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09AA05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Ramipril contains a medicine called ramipril. This belongs to a group of medicines called ACE inhibitors (Angiotensin Converting Enzyme Inhibitors).</p><p>&nbsp;</p><p>Ramipril works by:</p><p>-&nbsp;&nbsp; Decreasing your body&rsquo;s production of substances that could raise your blood pressure</p><p>-&nbsp;&nbsp; Making your blood vessels relax and widen</p><p>-&nbsp;&nbsp; Making it easier for your heart to pump blood around your body.</p><p>&nbsp;</p><p>Ramipril can be used:</p><p>-&nbsp;&nbsp; To treat high blood pressure (hypertension)</p><p>-&nbsp;&nbsp; To reduce the risk of you having a heart attack or stroke</p><p>-&nbsp;&nbsp; To reduce the risk or delay the worsening of kidney problems (whether or not you have diabetes)</p><p>-&nbsp;&nbsp; To treat your heart when it cannot pump enough blood to the rest of your body (heart failure)</p><p>-&nbsp;&nbsp; As treatment following heart attack (myocardial infarction) complicated with heart failure.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Ramipril:</strong></p><p>&nbsp;</p><p>-&nbsp;&nbsp; If you are allergic to ramipril, any other ACE inhibitor medicine or any of the other ingredients of this medicine (listed in section 6). Signs of an allergic reaction may include a rash, swallowing or breathing problems, swelling of your lips, face, throat or tongue</p><p>-&nbsp;&nbsp; If you have ever had a serious allergic reaction called &ldquo;angioedema&rdquo;. The signs include itching, hives (urticaria), red marks on the hands, feet and throat, swelling of the throat and tongue, swelling around the eyes and lips, difficulty breathing and swallowing</p><p>-&nbsp;&nbsp; If you are having dialysis or any other type of blood filtration. Depending on the machine that is used, Ramipril may not be suitable for you</p><p>-&nbsp;&nbsp; If you have kidney problems where the blood supply to your kidney is reduced (renal artery stenosis)</p><p>-&nbsp;&nbsp; During the last 6 months of pregnancy (see section below on &ldquo;Pregnancy and breast-feeding&rdquo;)</p><p>-&nbsp;&nbsp; If your blood pressure is abnormally low or unstable. Your doctor will need to make this assessment</p><p>-&nbsp;&nbsp; If you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren</p><p>-&nbsp;&nbsp; If you have taken or are currently taking sacubitril/valsartan, a medicine used to treat a type of long-term (chronic) heart failure in adults, as the risk of angioedema (rapid swelling under the skin in an area such as the throat) is increased.</p><p>&nbsp;</p><p>Do not take Ramipril if any of the above apply to you. If you are not sure, talk to your doctor before taking Ramipril.</p><p>&nbsp;</p><p>Warnings and precautions</p><p>Talk to your doctor or pharmacist before taking Ramipril:</p><p>-&nbsp;&nbsp; If you have heart, liver or kidney problems</p><p>-&nbsp;&nbsp; If you have lost a lot of body salts or fluids (through being sick (vomiting), having diarrhoea, sweating more than usual, being on a low salt diet, taking diuretics (water tablets) for a long time or having had dialysis)</p><p>-&nbsp;&nbsp; If you are going to have treatment to reduce your allergy to bee or wasp stings (desensitization)</p><p>-&nbsp;&nbsp; If you are going to receive an anaesthetic. This may be given for an operation or any dental work. You may need to stop your Ramipril treatment one day beforehand; ask your doctor for advice</p><p>-&nbsp;&nbsp; If you have high amounts of potassium in your blood (shown in blood test results)</p><p>-&nbsp;&nbsp; If you are taking medicines or have conditions which may decrease sodium levels in your blood. Your doctor may carry out regular blood tests, particularly for checking the levels of sodium in your blood especially if you are elderly</p><p>-&nbsp;&nbsp; If you are taking any of the following medicines, the risk of angioedema may be increased:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; racecadotril, a medicine used to treat diarrhoea.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to prevent organ transplant rejection and for cancer (e.g., temsirolimus, sirolimus, everolimus).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vildagliptin, a medicine used to treat diabetes.</p><p>-&nbsp;&nbsp; If you have collagen vascular disease such as scleroderma or systemic lupus erythematosus</p><p>-&nbsp;&nbsp; If you are taking any of the following medicines used to treat high blood pressure:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an angiotensin II receptor blockers (ARBs) (also known as sartans - for example valsartan, telmisartan, irbesartan), in particular if you have diabetes-related kidney problems.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aliskiren.</p><p>Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals.</p><p>See also information under the heading &ldquo;Do not take Ramipril&rdquo;.</p><p>&nbsp;</p><p>You must tell your doctor if you think that you are (or might become) pregnant. Ramipril is not recommended in the first 3 months of pregnancy and may cause serious harm to your baby after 3 months of pregnancy (see section below on &ldquo;Pregnancy and breast-feeding&rdquo;).</p><p>&nbsp;</p><p>Children and adolescents</p><p>Ramipril is not recommended for use in children and adolescents below 18 years of age because the safety and efficacy of ramipril in children has not yet been established.</p><p>&nbsp;</p><p>If any of the above apply to you (or you are not sure), talk to your doctor before taking Ramipril.</p><p>&nbsp;</p><p>Other medicines and Ramipril</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This is because Ramipril can affect the way some other medicines work. Also some medicines can affect the way Ramipril works.</p><p>&nbsp;</p><p><em>Tell your doctor if you are taking any of the following medicines. They can make Ramipril work less well:</em></p><p>-&nbsp;&nbsp; Medicines used to relieve pain and inflammation (e.g. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as ibuprofen or indometacin and acetylsalicylic acid)</p><p>-&nbsp;&nbsp; Medicines used for the treatment of low blood pressure, shock, cardiac failure, asthma or allergies such as ephedrine, noradrenaline or adrenaline. Your doctor will need to check your blood pressure.</p><p>&nbsp;</p><p><em>Tell your doctor if you are taking any of the following medicines. They can increase the chance of getting side effects if you take them with Ramipril:</em></p><p>-&nbsp;&nbsp; Medicines used to relieve pain and inflammation (e.g. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as ibuprofen or indometacin and acetylsalicylic acid)</p><p>-&nbsp;&nbsp; Medicines for cancer (chemotherapy)</p><p>-&nbsp;&nbsp; Diuretics (water tablets) such as furosemide</p><p>-&nbsp;&nbsp; Potassium supplements (including salt substitutes), potassium-sparing diuretics and other medicines that can increase the amount of potassium in your blood (e.g. trimethoprim and co- trimoxazole for infections caused by bacteria; ciclosporin, an immunosuppressant medicine used to prevent organ transplant rejection; and heparin, a medicine used to thin blood to prevent clots)</p><p>-&nbsp;&nbsp; Steroid medicines for inflammation such as prednisolone</p><p>-&nbsp;&nbsp; Allopurinol (used to lower the uric acid in your blood)</p><p>-&nbsp;&nbsp; Procainamide (for heart rhythm problems)</p><p>-&nbsp;&nbsp; Temsirolimus (for cancer)</p><p>-&nbsp;&nbsp; Sirolimus, everolimus (for prevention of graft rejection)</p><p>-&nbsp;&nbsp; Vildagliptin (used for treating type 2 diabetes)</p><p>-&nbsp;&nbsp; Racecadotril (used against diarrhoea).</p><p>&nbsp;</p><p>Your doctor may need to change your dose and/or to take other precautions:</p><p>If you are taking an angiotensin II receptor blocker (ARB) or aliskiren (see also information under the headings &ldquo;Do not take Ramipril&rdquo; and &ldquo;Warnings and precautions&rdquo;.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Tell your doctor if you are taking any of the following medicines. They may be affected by Ramipril:</em></p><p>&nbsp;</p><p>-&nbsp;&nbsp; Medicines for diabetes such as oral glucose lowering medicines and insulin. Ramipril may lower your blood sugar amounts. Check your blood sugar amounts closely while taking Ramipril</p><p>-&nbsp;&nbsp; Lithium (for mental health problems). Ramipril may increase the amount of lithium in your blood. Your lithium amount will need to be closely checked by your doctor.</p><p>&nbsp;</p><p>If any of the above apply to you (or you are not sure), talk to your doctor before taking Ramipril.</p><p>&nbsp;</p><p>Ramipril with food and alcohol</p><p>-&nbsp;&nbsp; Drinking alcohol with Ramipril may make you feel dizzy or light-headed. If you are concerned about how much you can drink while you are taking Ramipril, discuss this with your doctor as medicines used to reduce blood pressure and alcohol can have additive effects.</p><p>-&nbsp;&nbsp; Ramipril may be taken with or without food.</p><p>&nbsp;</p><p>Pregnancy and breast-feeding</p><p><strong>&nbsp;</strong></p><p><em>Pregnancy</em></p><p>You must tell your doctor if you think that you are (or might become) pregnant.</p><p>You should not take Ramipril in the first 12 weeks of pregnancy, and you must not take them at all after the 13th week as their use during pregnancy may possibly be harmful to the baby.</p><p>If you become pregnant while on Ramipril, tell your doctor immediately. A switch to a suitable alternative treatment should be carried out in advance of a planned pregnancy.</p><p>&nbsp;</p><p><em>Breast-feeding</em></p><p>You should not take Ramipril if you are breast-feeding. Ask your doctor or pharmacist for advice before taking any medicine.</p><p>Driving and using machines</p><p>You may feel dizzy, while taking Ramipril. This is more likely to happen when you start taking Ramipril or start taking a higher dose. If this happens, do not drive or use any tools or machines.</p><p>&nbsp;</p><p>Ramipril contains sodium</p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &ldquo;sodium- free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>Taking this medicine</p><p>-&nbsp;&nbsp; Take this medicine by mouth at the same time of the day each day.</p><p>-&nbsp;&nbsp; Swallow the tablets whole with liquid.</p><p>-&nbsp;&nbsp; Do not crush or chew the tablets.</p><p>&nbsp;</p><p>How much to take</p><p><strong>&nbsp;</strong></p><p><em>Treatment of high blood pressure</em></p><p>-&nbsp;&nbsp; The usual starting dose is 1.25 mg or 2.5 mg once daily.</p><p>-&nbsp;&nbsp; Your doctor will adjust the amount you take until your blood pressure is controlled.</p><p>-&nbsp;&nbsp; The maximum dose is 10 mg once daily.</p><p>-&nbsp;&nbsp; If you are already taking diuretics (water tablets), your doctor may stop or reduce the amount of the diuretic you take before beginning treatment with Ramipril.</p><p><em>To reduce the risk of you having a heart attack or stroke</em></p><p>-&nbsp;&nbsp; The usual starting dose is 2.5 mg once daily.</p><p>-&nbsp;&nbsp; Your doctor may then decide to increase the amount you take.</p><p>-&nbsp;&nbsp; The usual dose is 10 mg once daily.</p><p><em>Treatment to reduce or delay the worsening of kidney problems</em></p><p>-&nbsp;&nbsp; You may be started on a dose of 1.25 mg or 2.5 mg once daily.</p><p>-&nbsp;&nbsp; Your doctor will adjust the amount you are taking.</p><p>-&nbsp;&nbsp; The usual dose is 5 mg or 10 mg once daily.</p><p><em>Treatment of heart failure</em></p><p>-&nbsp;&nbsp; The usual starting dose is 1.25 mg once daily.</p><p>-&nbsp;&nbsp; Your doctor will adjust the amount you take.</p><p>-&nbsp;&nbsp; The maximum dose is 10 mg daily. Two administrations per day are preferable.</p><p><em>Treatment after you have had a heart attack</em></p><p>-&nbsp;&nbsp; The usual starting dose is 1.25 mg once daily to 2.5 mg twice daily.</p><p>-&nbsp;&nbsp; Your doctor will adjust the amount you take.</p><p>-&nbsp;&nbsp; The usual dose is 10 mg daily. Two administrations per day are preferable.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>Your doctor will reduce the initial dose and adjust your treatment more slowly.</p><p>&nbsp;</p><p>If you take more Ramipril than you should</p><p>Tell a doctor or go to the nearest hospital casualty department straight away. Do not drive to the hospital, get somebody else to take you or call for an ambulance. Take the medicine pack with you. This is so the doctor knows what you have taken.</p><p>&nbsp;</p><p>If you forget to take Ramipril</p><p>-&nbsp;&nbsp; If you miss a dose, take your normal dose when it is next due.</p><p>-&nbsp;&nbsp; Do not take a double dose to make up for a forgotten tablet.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Stop taking this medicine and see a doctor straight away, if you notice any of the following serious side effects - you may need urgent medical treatment:</p><p>-&nbsp;&nbsp; Swelling of the face, lips or throat which make it difficult to swallow or breathe, as well as itching and rashes. This could be a sign of a severe allergic reaction to this medicine</p><p>-&nbsp;&nbsp; Severe skin reactions including rash, ulcers in your mouth, worsening of a pre-existing skin disease, reddening, blistering or detachment of skin (such as Stevens-Johnson syndrome, toxic epidermal necrolysis or erythema multiform).</p><p>&nbsp;</p><p>&nbsp;</p><p>Tell your doctor immediately if you experience:</p><p>-&nbsp;&nbsp; Faster heart rate, uneven or forceful heartbeat (palpitations), chest pain, tightness in your chest or more serious problems including heart attack and stroke</p><p>-&nbsp;&nbsp; Shortness of breath or a cough. These could be signs of lung problems</p><p>-&nbsp;&nbsp; Bruising more easily, bleeding for longer than normal, any sign of bleeding (e.g. bleeding from the gums), purple spots blotching on the skin or getting infections more easily than usual, sore throat and fever, feeling tired, faint, dizzy or having pale skin. These can be signs of blood or bone marrow problems</p><p>-&nbsp;&nbsp; Severe stomach pain which may reach through to your back. This could be a sign of pancreatitis (inflammation of the pancreas)</p><p>-&nbsp;&nbsp; Fever, chills, tiredness, loss of appetite, stomach pain, feeling sick, yellowing of your skin or eyes (jaundice). These can be signs of liver problems such as hepatitis (inflammation of the liver) or liver damage.</p><p>&nbsp;</p><p>Other side effects include:</p><p>Tell your doctor if any of the following gets serious or lasts longer than a few days.</p><p>&nbsp;</p><p><strong>Common </strong>(may affect up to 1 in 10 people)</p><p>-&nbsp;&nbsp; Headache or feeling tired</p><p>-&nbsp;&nbsp; Feeling dizzy. This is more likely to happen when you start taking this medicine or start taking a higher dose</p><p>-&nbsp;&nbsp; Fainting, hypotension (abnormally low blood pressure), especially when you stand or sit up quickly</p><p>-&nbsp;&nbsp; Dry tickly cough, inflammation of your sinuses (sinusitis) or bronchitis, shortness of breath</p><p>-&nbsp;&nbsp; Stomach or gut pain, diarrhoea, indigestion, feeling or being sick</p><p>-&nbsp;&nbsp; Skin rash with or without raised area</p><p>-&nbsp;&nbsp; Chest pain</p><p>-&nbsp;&nbsp; Cramps or pain in your muscles</p><p>-&nbsp;&nbsp; Blood tests showing more potassium than usual in your blood.</p><p>&nbsp;</p><p><strong>Uncommon </strong>(may affect up to 1 in 100 people)</p><p>-&nbsp;&nbsp; Balance problems (vertigo)</p><p>-&nbsp;&nbsp; Itching and unusual skin sensations such as numbness, tingling, pricking, burning or creeping on your skin (paraesthesia)</p><p>-&nbsp;&nbsp; Loss or change in the way things taste</p><p>-&nbsp;&nbsp; Sleep problems</p><p>-&nbsp;&nbsp; Feeling depressed, anxious, more nervous than usual or restless</p><p>-&nbsp;&nbsp; Blocked nose, difficulty breathing or worsening of asthma</p><p>-&nbsp;&nbsp; A swelling in your gut called &ldquo;intestinal angioedema&rdquo; presenting with symptoms like abdominal pain, vomiting and diarrhoea</p><p>-&nbsp;&nbsp; Heartburn, constipation or dry mouth</p><p>-&nbsp;&nbsp; Passing more water (urine) than usual over the day</p><p>-&nbsp;&nbsp; Sweating more than usual</p><p>-&nbsp;&nbsp; Loss or decrease of appetite (anorexia)</p><p>-&nbsp;&nbsp; Increased or irregular heartbeats</p><p>-&nbsp;&nbsp; Swollen arms and legs. This may be a sign of your body holding onto more water than usual</p><p>-&nbsp;&nbsp; Flushing</p><p>-&nbsp;&nbsp; Blurred vision</p><p>-&nbsp;&nbsp; Pain in your joints</p><p>-&nbsp;&nbsp; Fever</p><p>-&nbsp;&nbsp; Sexual inability in men, reduced sexual desire in men or women</p><p>&nbsp;</p><p>-&nbsp;&nbsp; An increased number of certain white blood cells (eosinophilia) found during a blood test</p><p>-&nbsp;&nbsp; Blood tests showing changes in the way your liver, pancreas or kidneys are working.</p><p>&nbsp;</p><p><strong>Rare </strong>(may affect up to 1 in 1,000 people)</p><p>-&nbsp;&nbsp; Feeling shaky or confused</p><p>-&nbsp;&nbsp; Red and swollen tongue</p><p>-&nbsp;&nbsp; Severe flaking or peeling of the skin, itchy, lumpy rash</p><p>-&nbsp;&nbsp; Nail problem (e.g. loosening or separation of a nail from its bed)</p><p>-&nbsp;&nbsp; Skin rash or bruising</p><p>-&nbsp;&nbsp; Blotches on your skin and cold extremities</p><p>-&nbsp;&nbsp; Red, itchy, swollen or watery eyes</p><p>-&nbsp;&nbsp; Disturbed hearing and ringing in your ears</p><p>-&nbsp;&nbsp; Feeling weak</p><p>-&nbsp;&nbsp; Blood tests showing a decrease in the number of red blood cells, white blood cells or platelets or in the amount of haemoglobin.</p><p>&nbsp;</p><p><strong>Very rare </strong>(may affect up to 1 in 10,000 people)</p><p>-&nbsp;&nbsp; Being more sensitive to the sun than usual.</p><p>&nbsp;</p><p>Other side effects reported:</p><p>Tell your doctor if any of the following gets serious or lasts longer than a few days.</p><p>&nbsp;</p><p><strong>Not known </strong>(frequency cannot be estimated from the available data)</p><p>-&nbsp;&nbsp; Difficulty concentrating</p><p>-&nbsp;&nbsp; Swollen mouth</p><p>-&nbsp;&nbsp; Blood tests showing too few blood cells in your blood</p><p>-&nbsp;&nbsp; Blood tests showing less sodium than usual in your blood</p><p>-&nbsp;&nbsp; Concentrated urine (dark in colour), feel or are sick, have muscle cramps, confusion and fits which may be due to inappropriate ADH (anti-diuretic hormone) secretion. If you have these symptoms contact your doctor as soon as possible</p><p>-&nbsp;&nbsp; Fingers and toes changing colour when you are cold and then tingling or feeling painful when you warm up (Raynaud&#39;s phenomenon)</p><p>-&nbsp;&nbsp; Breast enlargement in men</p><p>-&nbsp;&nbsp; Slowed or impaired reactions</p><p>-&nbsp;&nbsp; Burning sensation</p><p>-&nbsp;&nbsp; Change in the way things smell</p><p>Hair loss.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the blister, carton or HDPE bottle after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store below 30&deg;C.</p><p>Store in the original package.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong></p><p>The active substance is ramipril.</p><p>Each tablet contains 5 mg of ramipril.</p><p>&nbsp;</p><p>The other ingredients are hypromellose, cellulose microcrystalline, starch, pregelatinised (maize), sodium hydrogen carbonate, sodium stearyl fumarate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                White, oblong, biplane with facet, both sides with breaking notch. Marking one-sided ‘R 5’. The tablet can be divided into equal doses.


The tablets are packed in aluminium/aluminium blisters and inserted in a carton or are packed in HDPE bottle with screw cap filled with silica gel as desiccant.

Pack sizes:
Blisters: 14, 20, 28, 30, 50, 60, 98, 100, 250 tablets

Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Hexal AG</p><p>Industriestr. 25</p><p>D-83607 Holzkirchen</p><p>Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                06/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي عقار راميبريل على دواء يُدعى راميبريل. ينتمي هذا الدَّواء إلى مجموعة من الأدوية تسمى مثبطات الإنْزيم المُحَوِّل للأَنْجيُوتَنْسينِ .</p><p dir="RTL">&nbsp;</p><p dir="RTL">يعمل عقار راميبريل بالشكل الآتي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من خلال خفض إنتاج جسمك للمواد التي قد ترفع ضغط دمك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من خلال إرخاء أوعيتك الدَّموية وتوسيعها.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من خلال تسهيل ضخ قلبك للدَّم إلى جميع أنحاء جسمك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُمكِن استخدام عقار راميبريل في الحالات الآتية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج ارتفاع ضغط الدَّم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; للحد من خطر إصابتك بنوبة قلبية أو سكتة دماغية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; للحد من خطر تفاقم مشاكل الكُلى أو لتأخيره (سواء أكنت مُصابًا بمرض السُّكَّرِي أم لا).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج قلبك عند عجزه عن ضخ ما يكفي من الدَّم إلى باقي أنحاء جسمك (فشل القلب).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بصفته علاجًا عقب الإصابة بنوبة قلبية (احتشاء عضلة القلب) مصحوبة بمضاعفات من ضمنها فشل القلب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول عقار راميبريل في الحالات الآتية</strong><strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه راميبريل أو تجاه أيٍّ من مثبطات الإنْزيم المُحَوِّل للأَنْجيُوتَنْسينِ الأخرى أو تجاه أي مكون من المكونات الأخرى بهذا الدَّواء (المدرجة في قسم: 6) قد تشمل العلامات التي تنم عن الإصابة بأحد تفاعلات الحساسية طفحًا جلديًّا، مشاكل بالبلع أو التَّنفس، تورُّم الشفتين أو الوجه أو الحَلق أو اللسان.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أُصِبت من قبل بتفاعل حساسية خطير يسمى &quot;وذمة وعائية&quot;. تشمل العلامات حكة، شرى (أرتكاريا)، علامات حمراء باليدين، والقدمين والحَلْق، تورم الحَلْق واللسان، تورمًا حول العينين والشفتين، صعوبة في التَّنفس والبلع.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تخضع للغسيل الكلوي أو أي نوع آخر من ترشيح الدَّم. استنادًا إلى الآلة المُستخدمة، قد لا يكون عقار راميبريل مناسبًا لك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل بالكُلى حيث ينخفض إمداد الكُلى خاصتك بالدَّم (تضيق في الشريان الكُلوي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أثناء الأشهر الستة (6) الأخيرة من الحمل (انظري أدناه قسم &quot;الحمل والرضاعة الطبيعيَّة&quot;).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان ضغط دمك منخفضًا أو غير مستقر بشكل غير طبيعي. سيتعين على طبيبك إجراء هذا التقييم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت مصابًا بمرض السُّكَّري أو تُعاني من قصور بوظائف الكُلى</strong>، ويتم علاجك بدواء خافض لضغط الدَّم يحتوي على أليسكيرين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد تناولت أو تتناول حاليًا ساكوبيتريل/ فالسارتان، أحد الأدوية التي تُستخدم لعلاج أحد أنواع فشل القلب طويل الأمد (المزمن) في البالغين؛ إذ يزداد خطر الإصابة بوذمة وعائية (تورم سريع تحت الجلد بمنطقة مثل الحَلْق).</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتناول عقار راميبريل إذا انطبق عليك أي مما سبق. إذا لم تكن متأكدًا، تحدَّث مع طبيبك قبل تناول عقار راميبريل</p><p dir="RTL">&nbsp;</p><p>تحذيرات واحتياطات</p><p dir="RTL">تحدَّث إلى طبيبك أو الصيدلي الخاص بك قبل تناول عقار راميبريل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك مشاكل بالقلب والكبد أو الكلى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا فقدت كمية كبيرة من &nbsp;أملاح أو &nbsp;سوائل الجسم (نتيجة إصابتك بإعياء (تقيؤ) أو إسهال، التعرُّق بوتيرة أكثر من المعتاد، اتباعك لنظام غذائي منخفض الملح، تناوُلك لمُدِرات البول (أقراص الماء) لمدة طويلة أو خضوعك لغسيل كلوي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت بصدد الخضوع للعلاج للحد من حساسيتك تجاه لدغات النحل والدبابير (إزالة التحسس).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت بصدد تلقي أحد أدوية التَّخدير. قد يتم إعطاؤك إياه قبل الخضوع لعملية أو إجراء بأسنانك. قد تحتاج إلى وقف الخضوع للعلاج بعقار راميبريل قبل الخضوع لمثل تلك العملية أو الإجراء بيوم واحد؛ يُرجى استشارة طبيبك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت مستويات البوتاسيوم بالدَّم لديك مرتفعة (كما هو مُوضح بنتائج اختبار الدَّم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أدوية أو كنت تعاني من حالات قد تخفض مستويات الصوديوم بدمك. قد يجري طبيبك اختبارات دم بصفة منتظمة؛ للتحقق من مستويات الصوديوم بالدَّم لديك خاصةً إذا كنت من كبار السن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يزداد خطر إصابتك بوذمة وعائية إذا كنت تتناول أيًّا من الأدوية الآتية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; راسيكادوتريل، دواء يُستخدم لعلاج الإِسْهال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تُستخدم للحيلولة دون رفض الجسم للعضو المزروع وللسرطان (على سبيل المثال: تيمسيروليموس، سيروليموس، إفيروليموس).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فيلداجليبتن، دواء يُستخدم لعلاج مرض السُّكَّرِي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مُصابًا بمرض وعائي كولاجيني مثل تصلب الجلد أو الذئبة الحمامية الجهازية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أيًّا من الأدوية التَّالية التي تُستَخدَم لعلاج ارتفاع ضغط الدَّم:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أحد حاصرات مستقبلات الأنجيوتنسينِ-2 (يُعرف أيضًا بالسارتانات - على سبيل المثال: فالسارتان، تلميسارتان، إربيسارتان)، لا سيما إذا كنت تُعاني من مشاكل بالكُلى ذات صلة بمرض السُّكَّري.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أليسكيرين.</p><p dir="RTL">قد يُجري لك طبيبك فحصًا لوظائف الكُلى وضغط الدَّم وكمية الإليكتروليتات (على سبيل المثال: البوتاسيوم) في دمك على فترات منتظمة.</p><p dir="RTL">انظر أيضًا المعلومات تحت عنوان: &quot;لا تتناول عقار راميبريل في الحالات الآتية&quot;.</p><p dir="RTL">يجب عليكِ إخبار طبيبكِ إذا كنتِ تعتقدين أنكِ حامل (أو قد تصبحين حاملًا). لا يُوصى بتناوُل عقار راميبريل خلال الأشهر الثلاثة الأولى من الحمل؛ وقد يلحق ضررًا خطيرًا بجنينك بعد انقضاء 3 أشهر من الحمل (انظري أدناه قسم: &quot;الحمل والرضاعة الطبيعيَّة&quot;).</p><p dir="RTL">&nbsp;</p><p>الأطفال والمراهقون</p><p dir="RTL">لا يُوصى باستخدام عقار راميبريل في الأطفال والمراهقين الذين تقل أعمارهم عن 18 عامًا؛ إذ لم يتم بعد إثبات أمان وفعَّالية عقار راميبريل في الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان أي مما سبق ينطبق عليك (أو إذا لم تكن متأكدًا مما سبق)، تحدَّث إلى طبيبك قبل تناول عقار راميبريل.</p><p dir="RTL">&nbsp;</p><p>تناوُل أدوية أخرى مع عقار راميبريل</p><p dir="RTL">يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى. وذلك لأنَّ عقار راميبريل قد يؤثر على طريقة عمل الأدوية الأخرى. قد تُؤثر أيضًا بعض الأدوية على طريقة عمل عقار راميبريل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>أخبر طبيبك إذا كنت تتناول أيًّا من الأدوية الآتية</em><em>: </em><em>فقد تحد هذه الأدوية من فَعَّاليَّة عقار راميبريل</em><em>:</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تُستَخدَم لتخفيف الألم والالتهاب (على سبيل المثال: مضادات الالتهاب غير الستيرويدية مثل إيبوبروفين أو إندوميثاسين وحمض أسيتيل الساليسيليك).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تُستخدَم لعلاج انخفاض ضغط الدَّم، الصدمة، الفشل القلبي، الربو أو الحساسية مثل الإفيدرين، النورادرينالين أو الأدرينالين. سيحتاج طبيبك إلى فحص ضغط الدَّم لديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>أخبر طبيبك إذا كنت تتناول أيًّا من الأدوية الآتية</em><em>: </em><em>فبإمكانها أن تزيد من احتمالات إصابتك بآثار جانبية إذا تناولتها بمصاحبة عقار راميبريل</em><em>:</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تُستَخدَم لتخفيف الألم والالتهاب (على سبيل المثال: مضادات الالتهاب غير الستيرويدية مثل إيبوبروفين أو إندوميثاسين وحمض أسيتيل الساليسيليك).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية علاج السرطان (العلاج الكيميائي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مُدِرات البول (أقراص الماء) مثل فوروسيميد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مكملات البوتاسيوم (بما في ذلك بدائل الملح)، مدرات البول المُوفرة للبوتاسيوم وغيرها من الأدوية التي بإمكانها أن تزيد من كمية البوتاسيوم بالدَّم لديك (على سبيل المثال: ترايميثوبريم وكو-ترايموكسازول لعلاج العدوى الناجمة عن البكتيريا؛ سيكلوسبورين، أحد الأدوية الكابتة للمناعة التي تُستخدم للحيلولة دون رفض الجسم للعضو المزروع؛ وهيبارين، أحد الأدوية التي تُستخدم لتسييل الدَّم للوقاية من الجلطات).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية الستيرويد لعلاج الالتهاب مثل بريدنيزولون.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألوبيورينول (يُستخدم لخفض حَمْض اليوريك بالدم لديك).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بروكايناميد (يُستخدم لعلاج مشاكل النظم القلبي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيمسيروليموس (للسرطان).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيروليموس، إفيروليموس (يُستخدمان للحيلولة دون رفض الطعم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فيلداجليبتن (يُستخدم لعلاج مرض السُّكَّرِي من النوع &quot;2&quot;).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; راسيكادوتريل (يُستخدم لعلاج الإسهال).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يحتاج طبيبك إلى تغيير جرعتك و/ أو اتخاذ احتياطات أخرى في الحالات الآتية:</p><p dir="RTL">إذا كنت تتناول حاصر مستقبل أنجيوتنسين-2 أو أليسكيرين (انظر أيضًا المعلومات الواردة تحت العناوين: &quot;لا تتناول عقار راميبريل في الحالات الآتية&quot;، و&quot;تحذيرات واحتياطات&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>أخبر طبيبك إذا كنت تتناول أيًّا من الأدوية الآتية</em><em>: </em><em>إذ قد تتأثر بعقار راميبريل</em><em>:</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية علاج مرض السُّكَّرِي مثل الأدوية الفموية الخافضة للجلوكوز والأنسولين. قد يخفض عقار راميبريل من كميات السكر بالدَّم لديك. تحقق من كميات السكر بالدَّم لديك عن كثب أثناء تناوُل عقار راميبريل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الليثيوم (لعلاج المشاكل الصحية النفسية). قد يزيد عقار راميبريل من كمية الليثيوم بالدَّم لديك. سيتعين على طبيبك مراقبة كمية الليثيوم لديك عن كثب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان أي مما سبق ينطبق عليك (أو إذا لم تكن متأكدًا مما سبق)، تحدَّث إلى طبيبك قبل تناول عقار راميبريل.</p><p dir="RTL">&nbsp;</p><p>تناوُل عقار راميبريل مع الطعام والكحوليات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يتسبب شرب الكحوليات مع عقار راميبريل في إصابتك بدوخة أو دوار. إذا كنت قلقًا حيال كمية الكحوليات التي يمكنك تناوُلها أثناء تناولك لعقار راميبريل، فناقش ذلك مع طبيبك؛ إذ قد يكون للأدوية المُستخدمة لخفض ضغط الدَّم والكحوليات تأثيرات مُضافة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُمكن تناوُل عقار راميبريل مع الطعام أو بدونه.</p><p dir="RTL">&nbsp;</p><p>الحمل والرضاعة الطبيعية</p><p dir="RTL"><em>الحَمْل</em></p><p dir="RTL">يجب عليكِ إخبار طبيبكِ إذا كنتِ تعتقدين أنكِ حامل (أو قد تصبحين حاملًا).</p><p dir="RTL">ينبغي عليكِ عدم تناوُل عقار راميبريل خلال الأسابيع الاثني عشر الأولى من الحمل، كما يجب عليكِ ألا تتناوليه بعد انقضاء الأسبوع الثالث عشر؛ حيث استخدامه أثناء الحمل قد يضر الجنين.</p><p dir="RTL">أخبري طبيبكِ فورًا إذا أصبحتِ حاملًا أثناء خضوعك للعلاج بعقار راميبريل. ينبغي الانتقال إلى علاج بديل مناسب قبل حدوث الحمل المُخطط له.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الرَّضاعة الطبيعية</em></p><p dir="RTL">ينبغي عليكِ ألا تتناولي عقار راميبريل إذا كنتِ تمارسين الرضاعة الطبيعيَّة. استشيري طبيبكِ أو الصيدلي قبل تناول أي دواء.</p><p>القيادة واستخدام الآلات</p><p dir="RTL">قد تشعر بدوخة أثناء تناوُل عقار راميبريل. من المُرجح حدوث ذلك عند بدئك في تناوُل عقار راميبريل أو عند بدئك في تناوُل جرعة أعلى. إذا حدث لك هذا، لا تمارس القيادة أو تستخدم أية أدوات أو آلات.</p><p dir="RTL">&nbsp;</p><p>يحتوي عقار راميبريل على الصوديوم</p><p>يحتوي هذا الدَّواء على أقل من 1 مللي مول من الصوديوم (23 مجم) في كل قرص، وهذا يعني أنه &quot;خالٍ من الصوديوم&quot; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول دائمًا هذا الدَّواء كما أخبرك طبيبك بالضبط. راجع طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية الاستخدام.</p><p dir="RTL">&nbsp;</p><p>تناول هذا الدواء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول هذا الدَّواء عن طريق الفم في الوقت نفسه من اليوم كل يوم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابتلع الأقراص كاملة، مع الماء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تسحق الأقراص أو تمضغها.</p><p>ما هي الكمية التي يجب أن تتناولها؟</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><em>لعلاج ارتفاع ضغط الدَّم</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبلغ جرعة البدء المعتادة 1.25 مجم أو 2.5 مجم مرَّة واحدة يوميًّا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيضبط طبيبك الكمية التي تتناولها إلى أن يتم التحكم بضغط الدَّم لديك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة القصوى هي 10 مجم مرَّة واحدة يوميًّا</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول بالفعل مُدِرات البول (أقراص الماء)، قد يوقفك طبيبك عن تناوُلها أو قد يحد من الكمية التي تتناولها منها قبل بدء العلاج بعقار راميبريل.</p><p dir="RTL"><em>للحد من خطر إصابتك بنوبة قلبية أو سكتة دماغية</em><em>.</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبلغ جرعة البدء المعتادة 2.5 مجم مرَّة واحدة يوميًّا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يقرر طبيبك لاحقًا زيادة الكمية التي تتناولها.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبلغ الجرعة المعتادة 10 مجم مرَّة واحدة يوميًّا.</p><p dir="RTL"><em>علاج للحد من تفاقم مشاكل الكُلى أو لتأخيره</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يتم البدء بإعطائك جرعة قدرها 1.25 مجم أو 2.5 مجم مرَّة واحدة يوميًّا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيضبط طبيبك الكمية التي تتناولها.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبلغ الجرعة المعتادة 5 مجم أو 10 مجم مرَّة واحدة يوميًّا.</p><p dir="RTL"><em>لعلاج فشل القلب</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبلغ جرعة البدء المعتادة 1.25 مجم مرَّة واحدة يوميًّا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيضبط طبيبك الكمية التي تتناولها.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة اليومية القصوى هي 10 مجم يوميًّا. يُفضل تناوُل العقار مرتين في اليوم</p><p dir="RTL"><em>علاج بعد تعرضك لنوبة قلبية</em><em>.</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتراوح جرعة البدء المعتادة بين 1.25 مجم مرَّة واحدة يوميًّا و2.5 مجم مرتين يوميًّا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيضبط طبيبك الكمية التي تتناولها.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة المعتادة هي 10 مجم يوميًّا يُفضل تناوُل العقار مرتين في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المرضى من كبار السن</strong></p><p dir="RTL">سيخفض طبيبك الجرعة الأولية وسيضبط علاجك بصورة أبطأ.</p><p dir="RTL">&nbsp;</p><p>إذا تناولت كمية أكثر مما يجب من عقار راميبريل</p><p dir="RTL">أخبر أحد الأطباء أو توجه إلى قسم الطوارئ بأقرب مستشفى على الفور. لا تقد إلى المستشفى بل اطلب من أحد آخر أن يقلَّك إليها أو اطلب سيارة إسعاف. خذ عبوة الدواء معك. ذلك ليعرف الطبيب ما تناولته.</p><p dir="RTL">&nbsp;</p><p>إذا أغفلت تناوُل عقار راميبريل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أغفلت تناوُل إحدى الجرعات، تناول جرعتك المعتادة في موعدها التالي المُقرر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول جرعة مضاعفة لتعويض قرص أغفلته.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر الطبيب أو الصيدلي الخاص بك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">&nbsp;</p><p>توقف عن تناول هذا الدواء، وتحدث إلى طبيبٍ فورًا إذا لاحظت أيًّا من الآثار الجانبية الخطيرة التالية - قد تكون بحاجة إلى علاج طبي عاجل:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورُّم الوجه، الشفتين أو الحَلْق مما يتسبب في صعوبة البلع أو التنفس، بالإضافة إلى الحكة والطفح الجلدي. قد تنم هذه العلامات عن إصابتك بتفاعل حساسية شديد تجاه هذا الدَّواء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات جلدية شديدة من ضمنها طفح جلدي، قرح بالفم لديك، تفاقم مرض جلدي قائم بالفعل، احمرار الجلد، ظهور بثور به أو انفصاله (مثل متلازمة ستيفنز جونسون، انحلال البشرة النخري التَّسممي أو الحُمامي متعددة الأشكال).</p><p dir="RTL">&nbsp;</p><p>اتصل بطبيبك على الفور إذا عانيت من أي من الآتي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسارع معدل ضربات القلب، عدم انتظام ضربات القلب أو شدتها (خَفَقان)، ألم بالصدر، ضيق بالصدر أو مشاكل أكثر خطورة بما في ذلك النوبة القلبية والسكتة الدماغية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق النفس أو سُعال. قد تنم هذه العلامات عن وجود مشاكل بالرئتين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سهولة الإصابة بكدمات، النزيف لمدة أطول من المُعتاد، أي علامة تنم عن نزيف (على سبيل المثال: نزيف من اللثة)، بقع أرجوانية ملطخة للجلد أو الإصابة بعدوى بشكل أسهل من المُعتاد، التهاب الحلق والحمى، الشعور بالتعب، إِغْماء (غَشيٌ) ، الدوخة أو شحوب الجلد. قد تنم هذه العلامات عن وجود مشاكل بالدم أو النخاع العظمي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام شديدة بالمعدة قد تمتد إلى ظهرك. قد تنم هذه العلامة عن التهاب البنكرياس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حُمّى، قشعريرة، تعب، فقدان الشهية، ألم المعدة، شعور بالإعياء، اصفرار الجلد أو العينين (يرقان) لديك. قد تنم هذه العلامات عن وجود مشاكل بالكبد مثل التهاب الكبد أو تلف الكبد.</p><p dir="RTL">&nbsp;</p><p>تشمل الآثار الجانبية الأخرى الآتي:</p><p dir="RTL">أخبِر طبيبك إذا أصبح أيٌّ من الآثار الجانبية التَّالية خطيرًا أو استمر لأكثر من بضعة أيام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة</strong> (قد تُؤثر على ما يصل إلى شخص واحد من بين كل ١٠&nbsp;أشخاص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع أو شعور بالتعب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالدوخة. من المُرجح حدوث ذلك عند بدئك في تناوُل هذا الدَّواء أو عند بدئك في تناوُل جرعة أعلى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إغماء، انخفاض ضغط الدَّم (انخفاض ضغط الدَّم بشكل غير طبيعي)، خاصةً عند النهوض أو الاعتدال سريعًا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سُعال جاف حساس، الْتِهاب الجُيوب الأنفية أو التهاب الشعب الهوائية، ضيق النفس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالمعدة أو الأمعاء، إسهال، عسر الهضم، شعور بإعياء أو الإصابة بإعياء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي مصحوب أو غير مصحوب ببروز المنطقة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالصدر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلصات أو ألم بعضلاتك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إبداء اختبارات دمك ارتفاعًا في مستوى البوتاسيوم بالدم لديك عن المعتاد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong> (قد تُؤثر على ما يصل إلى شخص واحد من بين كل ١٠٠ شخص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل بالتَّوازن (دوار).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة وأحاسيس غير مُعتادة بالجلد مثل تنميل، وخز، نخز، حُرقة أو زحف بجلدك (اضطرابات الإحساس).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان حاسة تذوُّق الأشياء أو حدوث تغيير بطريقة تذوقها.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل بالنوم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالاكتئاب، القلق، توتر أكثر من المعتاد أو تململ.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انسداد الأنف، صعوبة التنفس أو تفاقم الربو.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم بالأمعاء يُدعى &quot;وذمة وعائية معوية&quot; مصحوب بأعراض مثل ألم بالبطن، قيء وإسهال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حموضة (حُرْقَةُ الفُؤاد)، إمساك، أو جفاف الفم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التبول بوتيرة أكثر من المعتاد على مدار اليوم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعرُّق بوتيرة أكثر من المعتاد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية أو تراجعها.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ازدياد ضربات القلب أو عدم انتظامها.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الذراعين والساقين. قد تنم هذه العلامة عن احتفاظ جسمك بكمية مياه أكبر من المعتاد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الجلد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح الرؤية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالمفاصل لديك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمّى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عجز جنسي لدى الرجال، انخفاض الرغبة الجنسية في الرجال أو السيدات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ملاحظة ارتفاع عدد بعض خلايا الدَّم البيضاء (كثرة خلايا اليُوزينِيَّات) في أحد اختبارات الدم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إبداء اختبارات دمك تغييرات بطريقة عمل الكبد، البنكرياس أو الكُلى لديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة</strong> (قد تؤثر على ما يصل إلى شخص واحد من بين كل ١٠٠٠ شخص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالارتجاف أو الارتباك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار اللسان وتورمه.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الجلد أو تقشُّره بشكل شديد، طفح جلدي مثير للحكة ومتكتل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل بالأظافر (على سبيل المثال: انحلال أو انفصال الظفر عن فراشه).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي أو كدمات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور بقع بالجلد وبرودة الأطراف.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار العينين، أو الإصابة بحكة بهما، أو تورمهما أو إدماعهما.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب السمع وطنين بالأذنين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالضعف.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إبداء اختبارات دمك انخفاضًا في عدد خلايا الدَّم الحمراء، أو خلايا الدَّم البيضاء أو الصفائح الدَّموية أو كمية الهيموجلوبين لديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة جدًّا،</strong> (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10000 شخص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ازدياد حساسيتك تجاه الشمس عن المعتاد.</p><p dir="RTL">&nbsp;</p><p>تم الإبلاغ عن بعض الآثار الجانبية الأخرى:</p><p dir="RTL">أخبِر طبيبك إذا أصبح أيٌّ من الآثار الجانبية التَّالية خطيرًا أو استمر لأكثر من بضعة أيام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">غير معروفة<strong> </strong>(لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التركيز.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الفم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إبداء اختبارات دمك انخفاضًا بخلايا الدم لديك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إبداء اختبارات دمك انخفاضًا بمستوى الصوديوم بالدَّم لديك عن المعتاد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تَرَكّز البول (يصبح لونه داكنًا)، الشعور أو الإصابة بإعياء، الإصابة بتقلصات عضلية، ارتباك/التباس ونوبات تشنجية قد يكونون ناجمين عن الإفراز غير المتناسب للهرمون المُضاد لإدرار البول. إذا أُصِبت بهذه الأعراض فاتصل بطبيبك بأسرع ما يُمكِن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير لون أصابع اليدين والقدمين عند الشعور بالبرد ثم الشعور بوخز أو ألم عند الدفء (ظاهرة رينود).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم الثدي لدى الرجال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تباطؤ ردود الفعل أو اختلالها.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إحساس بالحُرقة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيير في رائحة الأشياء.</p><p>تساقط الشعر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدَّواء بعد تاريخ انتهاء الصلاحية المدون على الشريط أو العبوة الكارتونية أو على الزجاجة المصنوعة من البولي إيثيلين عالي الكثافة بعد كلمة &quot;EXP&quot;. يُشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">يخزن في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">يخزن داخل العبوة الأصلية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلصي من الأدوية عن طريق إلقائها في مياه الصَّرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعُد تستخدمها. ستساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">المادة الفعالة هي راميبريل</p><p dir="RTL">يحتوي كل قرص على 5 مجم منراميبريل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى هي الهيبروميلوز، السليلوز دقيق التبلور، النشا، (الذرة) سابقة التجلتُّن، كربونات هيدروجين الصوديوم، فومارات ستيريل الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">العقار عبارة عن أقراص بيضاء اللون، مستطيلة، ذات وجهين مسطحين، بكلا الجانبين حَزّ لتقسيمها. بأحد جانبيها علامة &quot;R 5&quot;. يمكن تقسيم القرص إلى جرعتين متساويين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأقراص مُعبأة في شرائط من الألومنيوم/ الألومنيوم بداخل عبوة كرتونية أو مُعبأة في زجاجة مصنوعة من البولي إيثيلين عالي الكثافة مُزودة بغطاء لولبي مملوء بجل السيليكا كمادة مُجففة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أحجام العبوات:</p><p dir="RTL">الشرائط: 14 و20 و28 و30 و50 و60 و98 و100 و250 قرصًا</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">هيكسال أيه جي</p><p dir="RTL">إندستراي شتراس 25</p><p dir="RTL">&nbsp;دي-83607 هولزكيرشن</p><p dir="RTL">ألمانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            06/2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ramipril 2.5 mg tablets Ramipril 5 mg tablets Ramipril 10 mg tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 2.5 mg of ramipril. Each tablet contains 5 mg of ramipril. Each tablet contains 10 mg of ramipril.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet.

2.5 mg tablets:
White, oblong, biplane with facet, both sides with breaking notch. Marking one-sided ‘R 2,5’. The tablet can be divided into equal doses.

5 mg tablets: White, oblong, biplane with facet, both sides with breaking notch. Marking one-sided ‘R 5’. The tablet can be divided into equal doses.

10 mg tablets: White, oblong, biplane with facet, both sides with breaking notch. Marking one-sided ‘R 10’. The tablet can be divided into equal doses.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Treatment of hypertension</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Cardiovascular prevention: reduction of cardiovascular morbidity and mortality in patients with:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; manifest atherothrombotic cardiovascular disease (history of coronary heart disease or stroke, or peripheral vascular disease) or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diabetes with at least one cardiovascular risk factor (see section 5.1).</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Treatment of renal disease:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor (see section 5.1),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Manifest glomerular non diabetic nephropathy as defined by macroproteinuria &ge; 3 g/day (see section 5.1).</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Treatment of symptomatic heart failure.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started &gt; 48 hours following acute myocardial infarction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p>It is recommended that Ramipril is taken each day at the same time of the day.</p><p>&nbsp;</p><p>Ramipril can be taken before, with or after meals, because food intake does not modify its bioavailability (see section 5.2).</p><p>&nbsp;</p><p>[Ramipril] has to be swallowed with liquid. It must not be chewed or crushed.</p><p>&nbsp;</p><p><em><u>Adults</u></em></p><p><em>&nbsp;</em></p><p><u>Diuretic-Treated patients</u></p><p>Hypotension may occur following initiation of therapy with Ramipril; this is more likely in patients who are being treated concurrently with diuretics. Caution is therefore recommended since these patients may be volume and/or salt depleted.</p><p>If possible, the diuretic should be discontinued 2 to 3 days before beginning therapy with Ramipril (see section 4.4).</p><p>In hypertensive patients in whom the diuretic is not discontinued, therapy with Ramipril should be initiated with a 1.25 mg dose. Renal function and serum potassium should be monitored. The subsequent dose of Ramipril should be adjusted according to blood pressure target.</p><p>&nbsp;</p><p>Hypertension</p><p>The dose should be individualised according to the patient profile (see section 4.4) and blood pressure control.</p><p>&nbsp;</p><p>Ramipril may be used in monotherapy or in combination with other classes of antihypertensive medicinal products (see sections 4.3, 4.4, 4.5 and 5.1).</p><p>&nbsp;</p><p><u>Starting dose</u></p><p>Ramipril should be started gradually with an initial recommended dose of 2.5 mg daily.</p><p>Patients with a strongly activated renin-angiotensin-aldosterone system may experience an excessive drop in blood pressure following the initial dose. A starting dose of 1.25 mg is recommended in such patients and the initiation of treatment should take place under medical supervision (see section 4.4).</p><p>&nbsp;</p><p><u>Titration and maintenance dose</u></p><p>The dose can be doubled at interval of two to four weeks to progressively achieve target blood pressure; the maximum permitted dose of Ramipril is 10 mg daily. Usually the dose is administered once daily.</p><p>&nbsp;</p><p>Cardiovascular prevention</p><p><strong>&nbsp;</strong></p><p><u>Starting dose</u></p><p>The recommended initial dose is 2.5 mg of Ramipril once daily.</p><p>&nbsp;</p><p><u>Titration and maintenance dose</u></p><p>Depending on the patient&rsquo;s tolerability to the active substance, the dose should be gradually increased. It is recommended to double the dose after one or two weeks of treatment and - after another two to three weeks - to increase it up to the target maintenance dose of 10 mg Ramipril once daily.</p><p>&nbsp;</p><p>See also posology on diuretic treated patients above.</p><p>&nbsp;</p><p>Treatment of renal disease</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>In patients with diabetes and microalbuminuria:</em></p><p><em>&nbsp;</em></p><p><u>Starting dose:</u></p><p>The recommended initial dose is 1.25 mg of Ramipril once daily.</p><p>&nbsp;</p><p><u>Titration and maintenance dose</u></p><p>Depending on the patient&#39;s tolerability to the active substance, the dose is subsequently increased. Doubling the once daily dose to 2.5 mg after two weeks and then to 5 mg after a further two weeks is recommended.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>In patients with diabetes and at least one cardiovascular risk:</em></p><p><em>&nbsp;</em></p><p><u>Starting dose:</u></p><p>The recommended initial dose is 2.5 mg of Ramipril once daily.</p><p>&nbsp;</p><p><u>Titration and maintenance dose</u></p><p>Depending on the patient&rsquo;s tolerability to the active substance, the dose is subsequently increased. Doubling the daily dose to 5 mg Ramipril after one or two weeks and then to 10 mg Ramipril after a further two or three weeks is recommended. The target daily dose is 10 mg.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>In patients with non- diabetic nephropathy as defined by macroproteinuria &ge; 3 g/day:</em></p><p>&nbsp;</p><p><u>Starting dose:</u></p><p>The recommended initial dose is 1.25 mg of Ramipril once daily.</p><p>&nbsp;</p><p><u>Titration and maintenance dose</u></p><p>Depending on the patient&rsquo;s tolerability to the active substance, the dose is subsequently increased. Doubling the once daily dose to 2.5 mg after two weeks and then to 5 mg after a further two weeks is recommended.</p><p>&nbsp;</p><p>Symptomatic heart failure</p><p><strong>&nbsp;</strong></p><p><u>Starting dose</u></p><p>In patients stabilized on diuretic therapy, the recommended initial dose is 1.25 mg daily.</p><p>&nbsp;</p><p><u>Titration and maintenance dose</u></p><p>Ramipril should be titrated by doubling the dose every one to two weeks up to a maximum daily dose of 10 mg. Two administrations per day are preferable.</p><p>&nbsp;</p><p>Secondary prevention after acute myocardial infarction and with heart failure</p><p><strong>&nbsp;</strong></p><p><u>Starting dose</u></p><p>After 48 hours, following myocardial infarction in a clinically and haemodynamically stable patient, the starting dose is 2.5 mg twice daily for three days. If the initial 2.5 mg dose is not tolerated a dose of 1.25 mg twice a day should be given for two days before increasing to 2.5 mg and 5 mg twice a day. If the dose cannot be increased to 2.5 mg twice a day the treatment should be withdrawn.</p><p>See also posology on diuretic treated patients above. <u>Titration and maintenance dose</u></p><p>The daily dose is subsequently increased by doubling the dose at intervals of one to three days up to</p><p>the target maintenance dose of 5 mg twice daily.</p><p>&nbsp;</p><p>The maintenance dose is divided in 2 administrations per day where possible.</p><p>&nbsp;</p><p>If the dose cannot be increased to 2.5 mg twice a day treatment should be withdrawn. Sufficient experience is still lacking in the treatment of patients with severe (NYHA IV) heart failure immediately after myocardial infarction. Should the decision be taken to treat these patients, it is recommended that therapy be started at 1.25 mg once daily and that particular caution be exercised in any dose increase.</p><p>&nbsp;</p><p><em><u>Special populations</u></em></p><p><em>&nbsp;</em></p><p><em>Patients with renal impairment</em></p><p>Daily dose in patients with renal impairment should be based on creatinine clearance (see section 5.2):</p><p>-&nbsp;&nbsp; if creatinine clearance is &ge; 60 ml/min, it is not necessary to adjust the initial dose (2.5 mg/day); the maximal daily dose is 10 mg;</p><p>-&nbsp;&nbsp; if creatinine clearance is between 30-60 ml/min, it is not necessary to adjust the initial dose (2.5 mg/day); the maximal daily dose is 5 mg;</p><p>-&nbsp;&nbsp; if creatinine clearance is between 10-30 ml/min, the initial dose is 1.25 mg/day and the maximal daily dose is 5 mg;</p><p>&nbsp;</p><p>-&nbsp;&nbsp; in haemodialysed hypertensive patients: ramipril is slightly dialysable; the initial dose is 1.25 mg/day and the maximal daily dose is 5 mg; the medicinal product should be administered few hours after haemodialysis is performed.</p><p>&nbsp;</p><p><em>Patients with hepatic impairment (see section 5.2)</em></p><p>In patients with hepatic impairment, treatment with Ramipril must be initiated only under close medical supervision and the maximum daily dose is 2.5 mg Ramipril.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>Initial doses should be lower and subsequent dose titration should be more gradual because of greater chance of undesirable effects especially in very old and frail patients. A reduced initial dose of 1.25 mg ramipril should be considered.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of ramipril in children has not yet been established.</p><p>Currently available data for ramipril are described in sections 4.8, 5.1, 5.2 and 5.3 but no specific recommendation on posology can be made.</p><p>&nbsp;</p><p><u>Method of administration </u>Oral use</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -	Hypersensitivity to the active substance, to any of the excipients listed in section 6.1 or any other ACE (Angiotensin Converting Enzyme) inhibitors
-	History of angioedema (hereditary, idiopathic or due to previous angioedema with ACE inhibitors or AIIRAs)
-	Extracorporeal treatments leading to contact of blood with negatively charged surfaces (see section 4.5)
-	Significant bilateral renal artery stenosis or renal artery stenosis in a single functioning kidney
-	2nd  and 3rd  trimesters of pregnancy (see sections 4.4 and 4.6)
-	Ramipril must not be used in patients with hypotensive or haemodynamically unstable states
-	The concomitant use of Ramipril with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73m2) (see sections 4.5 and 5.1)
-	Concomitant use with sacubitril/valsartan therapy. Ramipril must not be initiated earlier than 36 hours after the last dose of sacubitril/valsartan (see also sections 4.4 and 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Special populations</u></em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Pregnancy: </em>ACE inhibitors such as ramipril, or Angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. Unless continued ACE inhibitor/ AIIRAs therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ACE inhibitors/ AIIRAs should be stopped</p><p>&nbsp;</p><p>immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Patients at particular risk of hypotension</em></p><p><em>&nbsp;</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp; <em>Patients with strongly activated renin-angiotensin-aldosterone system</em></p><p>Patients with strongly activated renin-angiotensin-aldosterone system are at risk of an acute pronounced fall in blood pressure and deterioration of renal function due to ACE inhibition, especially when an ACE inhibitor or a concomitant diuretic is given for the first time or at first dose increase.</p><p>&nbsp;</p><p>Significant activation of renin-angiotensin-aldosterone system is to be anticipated and medical supervision including blood pressure monitoring is necessary, for example in:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; patients with severe hypertension</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; patients with decompensated congestive heart failure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; patients with haemodynamically relevant left ventricular inflow or outflow impediment (e.g. stenosis of the aortic or mitral valve)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; patients with unilateral renal artery stenosis with a second functional kidney</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; patients in whom fluid or salt depletion exists or may develop (including patients with diuretics)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; patients with liver cirrhosis and/or ascites</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; patients undergoing major surgery or during anaesthesia with agents that produce hypotension.</p><p>Generally, it is recommended to correct dehydration, hypovolaemia or salt depletion before initiating treatment (in patients with heart failure, however, such corrective action must be carefully weighed out against the risk of volume overload).</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; <em>Dual blockade of the renin-angiotensin-aldosterone system (RAAS)</em></p><p>There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).</p><p>If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.</p><p>ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; <em>Transient or persistent heart failure post MI</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp; <em>Patients at risk of cardiac or cerebral ischemia in case of acute hypotension</em></p><p>The initial phase of treatment requires special medical supervision.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Elderly</em></p><p>See section 4.2.</p><p>&nbsp;</p><p><em><u>Surgery</u></em></p><p>It is recommended that treatment with angiotensin converting enzyme inhibitors such as ramipril should be discontinued where possible one day before surgery.</p><p>&nbsp;</p><p><em><u>Monitoring of renal function</u></em></p><p>&nbsp;</p><p>Renal function should be assessed before and during treatment and dose adjusted especially in the initial weeks of treatment. Particularly careful monitoring is required in patients with renal impairment (see section 4.2). There is a risk of impairment of renal function, particularly in patients with congestive heart failure or after a renal transplant.</p><p>&nbsp;</p><p><em><u>Angioedema</u></em></p><p>Angioedema has been reported in patients treated with ACE inhibitors including ramipril (see section 4.8).</p><p>Concomitant use of ACE inhibitors with sacubitril/valsartan is contraindicated due to the increased risk of angioedema. Treatment with sacubitril/valsartan must not be initiated earlier than 36 hours after the last dose of [Ramipril]. Treatment with [Ramipril] must not be initiated earlier than 36 hours after the last dose of sacubitril/valsartan (see sections 4.3 and 4.5).</p><p>&nbsp;</p><p>Concomitant use of ACE inhibitors with racecadotril, mTOR inhibitors (e.g. sirolimus, everolimus, temsirolimus) and vildagliptin may lead to an increased risk of angioedema (e.g. swelling of the airways or tongue, with or without respiratory impairment) (see section 4.5). Caution should be used when starting racecadotril, mTOR inhibitors (e.g. sirolimus, everolimus, temsirolimus) and vildagliptin in a patient already taking an ACE inhibitor.</p><p>&nbsp;</p><p>Intestinal angioedema has been reported in patients treated with ACE inhibitors including Ramipril (see section 4.8). These patients presented with abdominal pain (with or without nausea or vomiting).</p><p>&nbsp;</p><p>In case of angioedema, Ramipril must be discontinued.</p><p>Emergency therapy should be instituted promptly. Patient should be kept under observation for at least 12 to 24 hours and discharged after complete resolution of the symptoms.</p><p>&nbsp;</p><p><em><u>Anaphylactic reactions during desensitization</u></em></p><p>The likelihood and severity of anaphylactic and anaphylactoid reactions to insect venom and other allergens are increased under ACE inhibition. A temporary discontinuation of Ramipril should be considered prior to desensitization.</p><p>&nbsp;</p><p><em><u>Electrolyte monitoring: hyperkalaemia</u></em></p><p>Hyperkalaemia has been observed in some patients treated with ACE inhibitors including Ramipril. ACE inhibitors can cause hyperkalaemia because they inhibit the release of aldosterone. The effect is usually not significant in patients with normal renal function. However, in patients with impaired renal function, age (&gt; 70 years), uncontrolled diabetes mellitus, conditions such as dehydration, acute cardiac decompensation, metabolic acidosis, and/or in patients taking potassium supplements (including salt substitutes), potassium-sparing diuretics, trimethoprim or co- trimoxazole also known as trimethoprim/sulfamethoxazole and especially aldosterone antagonists or angiotensin-receptor blockers, hyperkalaemia can occur. Potassium-sparing diuretics and angiotensin- receptor blockers should be used with caution in patients receiving ACE inhibitors, and serum potassium and renal function should be monitored (see section 4.5).</p><p>&nbsp;</p><p><em><u>Electrolyte monitoring: hyponatremia</u></em></p><p>Syndrome of Inappropriate Anti-diuretic Hormone (SIADH) and subsequent hyponatremia has been observed in some patients treated with ramipril. It is recommended that serum sodium levels be monitored regularly in the elderly and in other patients at risk of hyponatremia.</p><p>&nbsp;</p><p><em><u>Neutropenia/agranulocytosis</u></em></p><p>Neutropenia/agranulocytosis, as well as thrombocytopenia and anaemia, have been rarely seen and bone marrow depression has also been reported. It is recommended to monitor the white blood cell</p><p>&nbsp;</p><p>count to permit detection of a possible leucopoenia. More frequent monitoring is advised in the initial phase of treatment and in patients with impaired renal function, those with concomitant collagen disease (e.g. lupus erythematosus or scleroderma), and all those treated with other medicinal products that can cause changes in the blood picture (see sections 4.5 and 4.8).</p><p>&nbsp;</p><p><em><u>Ethnic differences</u></em></p><p>ACE inhibitors cause higher rate of angioedema in black patients than in non black patients.</p><p>As with other ACE inhibitors, ramipril may be less effective in lowering blood pressure in black people than in non black patients, possibly because of a higher prevalence of hypertension with low renin level in the black hypertensive population.</p><p>&nbsp;</p><p><em><u>Cough</u></em></p><p>Cough has been reported with the use of ACE inhibitors. Characteristically, the cough is non- productive, persistent and resolves after discontinuation of therapy. ACE inhibitor-induced cough should be considered as part of the differential diagnosis of cough.</p><p>&nbsp;</p><p><em><u>Special warnings regarding excipients</u></em></p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).</p><p>&nbsp;</p><p><u>Contra-indicated combinations</u></p><p>&nbsp;</p><p>Extracorporeal treatments leading to contact of blood with negatively charged surfaces such as dialysis or haemofiltration with certain high-flux membranes (e.g. polyacrylonitril membranes) and low density lipoprotein apheresis with dextran sulphate due to increased risk of severe anaphylactoid reactions (see section 4.3). If such treatment is required, consideration should be given to using a different type of dialysis membrane or a different class of antihypertensive agent.</p><p>&nbsp;</p><p><em>Medicinal products increasing the risk of angioedema: </em>Concomitant use of ACE inhibitors with sacubitril/valsartan is contraindicated as this increases the risk of angioedema (see section 4.3 and 4.4).</p><p>&nbsp;</p><p><u>Precautions for use</u></p><p>&nbsp;</p><p><em>Medicinal products increasing the risk of angioedema: </em>Concomitant use of ACE inhibitors with racecadotril, mTOR inhibitors (e.g. sirolimus, everolimus, temsirolimus) and vildagliptin may lead to an increased risk for angioedema (see section 4.4).</p><p>&nbsp;</p><p><em>Potassium sparing diuretics, potassium supplements or potassium-containing salt substitutes: </em>Although serum potassium usually remains within normal limits, hyperkalaemia may occur in some patients treated with ramipril. Potassium sparing diuretics (e.g. spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. Care should also be taken when ramipril is co-administered with other</p><p>&nbsp;</p><p>agents that increase serum potassium, such as trimethoprim and co-trimoxazole (trimethoprim/sulfamethoxazole) as trimethoprim is known to act as a potassium-sparing diuretic like amiloride. Therefore, the combination of ramipril with the above-mentioned medicinal products is not recommended. If concomitant use is indicated, they should be used with caution and with frequent monitoring of serum potassium.</p><p>&nbsp;</p><p><em>Ciclosporin: </em>Hyperkalaemia may occur during concomitant use of ACE inhibitors with ciclosporin. Monitoring of serum potassium is recommended.</p><p>&nbsp;</p><p><em>Heparin: </em>Hyperkalaemia may occur during concomitant use of ACE inhibitors with heparin. Monitoring of serum potassium is recommended.</p><p>&nbsp;</p><p><em>Antihypertensive agents (e.g. diuretics) and other substances that may decrease blood pressure (e.g. nitrates, tricyclic antidepressants, anaesthetics, acute alcohol intake, baclofen, alfuzosin, doxazosin, prazosin, tamsulosin, terazosin): </em>Potentiation of the risk of hypotension is to be anticipated (see section 4.2 for diuretics).</p><p>&nbsp;</p><p><em>Vasopressor sympathomimetics and other substances (e.g. isoproterenol, dobutamine, dopamine, epinephrine) that may reduce the antihypertensive effect of Ramipril: </em>Blood pressure monitoring is recommended.</p><p>&nbsp;</p><p><em>Allopurinol, immunosuppressants, corticosteroids, procainamide, cytostatics and other substances that may change the blood cell count: </em>Increased likelihood of haematological reactions (see section 4.4).</p><p>&nbsp;</p><p><em>Lithium salts: </em>Excretion of lithium may be reduced by ACE inhibitors and therefore lithium toxicity may be increased. Lithium level must be monitored.</p><p>&nbsp;</p><p><em>Antidiabetic agents including insulin: </em>Hypoglycaemic reactions may occur. Blood glucose monitoring is recommended.</p><p>&nbsp;</p><p><em>Non-steroidal anti-inflammatory medicinal products and acetylsalicylic acid: </em>Reduction of the antihypertensive effect of Ramipril is to be anticipated. Furthermore, concomitant treatment of ACE inhibitors and NSAIDs may lead to an increased risk of worsening of renal function and to an increase in kalaemia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>Ramipril is not recommended during the first trimester of pregnancy (see section 4.4) and is contraindicated during the second and third trimesters of pregnancy (see section 4.3).</p><p><strong>&nbsp;</strong></p><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Unless continued ACE inhibitor therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately, and, if appropriate, alternative therapy should be started.</p><p>&nbsp;</p><p>ACE inhibitor/ Angiotensin II Receptor Antagonist (AIIRA) therapy exposure during the second and third trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia). (See also 5.3 &#39;Preclinical safety data&#39;). Should exposure to ACE inhibitor have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended. Newborns whose mothers have taken ACE inhibitors should be closely observed for hypotension, oliguria and hyperkalaemia (see also sections 4.3 and 4.4).</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Because insufficient information is available regarding the use of ramipril during breast-feeding (see section 5.2), ramipril is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Some adverse reactions (e.g. symptoms of a reduction in blood pressure such as dizziness) may impair the patient&rsquo;s ability to concentrate and react and, therefore, constitute a risk in situations where these abilities are of particular importance (e.g. operating a vehicle or machinery).</p><p>&nbsp;</p><p>This can happen especially at the start of treatment, or when changing over from other preparations. After the first dose or subsequent increases in dose it is not advisable to drive or operate machinery for several hours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Summary of safety profile</u></em></p><p><em>&nbsp;</em></p><p>The safety profile of ramipril includes persistent dry cough and reactions due to hypotension. Serious adverse reactions include angioedema, hyperkalaemia, renal or hepatic impairment, pancreatitis, severe skin reactions and neutropenia/agranulocytosis.</p><p>&nbsp;</p><p><em><u>Tabulated list of adverse reactions</u></em></p><p><em>&nbsp;</em></p><p>Adverse reactions frequency is defined using the following convention:</p><p>&nbsp;</p><p>Very common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&ge; 1/10)</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&ge; 1/100 to &lt; 1/10)</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&ge; 1/1,000 to &lt; 1/100)</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&ge; 1/10,000 to &lt; 1/1,000)</p><p>Very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&lt; 1/10,000)</p><p>Not known&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (cannot be estimated from the available data)</p><p>&nbsp;</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Frequency / System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Eosinophilia</p></td><td style="vertical-align:top"><p>White blood cell count</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Bone marrow failure,</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="13" style="vertical-align:top"><p><strong>system disorders</strong></p></td><td rowspan="13" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="13" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>decreased</p></td><td rowspan="13" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>pancytopenia,</p></td></tr><tr><td style="vertical-align:top"><p>(including</p></td><td style="vertical-align:top"><p>haemolytic</p></td></tr><tr><td style="vertical-align:top"><p>neutropenia</p></td><td style="vertical-align:top"><p>anaemia</p></td></tr><tr><td style="vertical-align:top"><p>or agranulo-</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>cytosis), red</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>blood cell</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>count</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>decreased,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>haemoglobin</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>decreased,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>platelet</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>count</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>decreased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system</strong></p></td><td rowspan="7" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="7" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="7" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="7" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylactic</p></td></tr><tr><td style="vertical-align:top"><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>or</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>anaphylactoid</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>reactions,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>antinuclear</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>antibody</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>increased</p></td></tr><tr><td style="vertical-align:top"><p><strong>Endocrine</strong></p></td><td rowspan="6" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="6" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="6" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="6" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Syndrome of</p></td></tr><tr><td style="vertical-align:top"><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>inappropriate</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>antidiuretic</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hormone</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>secretion</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(SIADH)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>Blood potassium increased</p></td><td style="vertical-align:top"><p>Anorexia, decreased appetite</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Blood sodium decreased</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td rowspan="5" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Depressed mood, anxiety, nervousness,</p></td><td rowspan="5" style="vertical-align:top"><p>Confusional state</p></td><td rowspan="5" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="5" style="vertical-align:top"><p>Disturbance in attention</p></td></tr><tr><td style="vertical-align:top"><p>restlessness,</p></td></tr><tr><td style="vertical-align:top"><p>sleep disorder</p></td></tr><tr><td style="vertical-align:top"><p>including</p></td></tr><tr><td style="vertical-align:top"><p>somnolence</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system</strong></p></td><td style="vertical-align:top"><p>Headache,</p></td><td style="vertical-align:top"><p>Vertigo,</p></td><td style="vertical-align:top"><p>Tremor,</p></td><td rowspan="14" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cerebral</p></td></tr><tr><td style="vertical-align:top"><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>dizziness</p></td><td style="vertical-align:top"><p>paraesthesia,</p></td><td style="vertical-align:top"><p>balance</p></td><td style="vertical-align:top"><p>ischaemia</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>ageusia,</p></td><td style="vertical-align:top"><p>disorder</p></td><td style="vertical-align:top"><p>including</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>dysgeusia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>ischaemic</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>stroke and</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>transient</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>ischaemic</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>attack,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>psychomotor</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>skills</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>impaired,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>burning</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>sensation,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>parosmia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Visual disturbance including blurred vision</p></td><td style="vertical-align:top"><p>Conjunctivitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hearing impaired, tinnitus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac</strong></p></td><td rowspan="12" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myocardial</p></td><td rowspan="12" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="12" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="12" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>ischaemia</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>including</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>angina</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>pectoris or</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>myocardial</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>infarction,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>tachycardia,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>arrhythmia,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>palpitations,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>oedema</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>peripheral</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular</strong></p></td><td style="vertical-align:top"><p>Hypotension,</p></td><td rowspan="5" style="vertical-align:top"><p>Flushing</p></td><td style="vertical-align:top"><p>Vascular</p></td><td rowspan="5" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Raynaud&rsquo;s</p></td></tr><tr><td style="vertical-align:top"><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>orthostatic</p></td><td style="vertical-align:top"><p>stenosis,</p></td><td style="vertical-align:top"><p>phenomenon</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>blood pressure</p></td><td style="vertical-align:top"><p>hypoperfusio</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>decreased,</p></td><td style="vertical-align:top"><p>n, vasculitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>syncope</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory,</strong></p></td><td style="vertical-align:top"><p>Non-productive</p></td><td style="vertical-align:top"><p>Bronchospasm</p></td><td rowspan="6" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="6" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="6" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>thoracic and</strong></p></td><td style="vertical-align:top"><p>tickling cough,</p></td><td style="vertical-align:top"><p>including</p></td></tr><tr><td style="vertical-align:top"><p><strong>mediastinal</strong></p></td><td style="vertical-align:top"><p>bronchitis,</p></td><td style="vertical-align:top"><p>asthma</p></td></tr><tr><td style="vertical-align:top"><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>sinusitis,</p></td><td style="vertical-align:top"><p>aggravated,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>dyspnoea</p></td><td style="vertical-align:top"><p>nasal</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>congestion</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal</strong></p></td><td style="vertical-align:top"><p>Gastrointestinal</p></td><td style="vertical-align:top"><p>Pancreatitis</p></td><td rowspan="19" style="vertical-align:top"><p>Glossitis</p></td><td rowspan="19" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Aphtous</p></td></tr><tr><td style="vertical-align:top"><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>inflammation,</p></td><td style="vertical-align:top"><p>(cases of fatal</p></td><td style="vertical-align:top"><p>stomatitis</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>digestive</p></td><td style="vertical-align:top"><p>outcome have</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>disturbances,</p></td><td style="vertical-align:top"><p>been very</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>abdominal</p></td><td style="vertical-align:top"><p>exceptionally</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>discomfort,</p></td><td style="vertical-align:top"><p>reported with</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>dyspepsia,</p></td><td style="vertical-align:top"><p>ACE</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>diarrhoea,</p></td><td style="vertical-align:top"><p>inhibitors),</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>nausea,</p></td><td style="vertical-align:top"><p>pancreatic</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>vomiting</p></td><td style="vertical-align:top"><p>enzymes</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>increased,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>small bowel</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>angioedema,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>abdominal</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>pain upper</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>including</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>gastritis,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>constipation,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>dry mouth</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary</strong></p></td><td rowspan="4" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hepatic</p></td><td style="vertical-align:top"><p>Jaundice</p></td><td rowspan="4" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Acute hepatic</p></td></tr><tr><td style="vertical-align:top"><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>enzymes</p></td><td style="vertical-align:top"><p>cholestatic,</p></td><td style="vertical-align:top"><p>failure,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>and/or</p></td><td style="vertical-align:top"><p>hepatocellul</p></td><td style="vertical-align:top"><p>cholestatic or</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>bilirubin</p></td><td style="vertical-align:top"><p>ar damage</p></td><td style="vertical-align:top"><p>cytolytic</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>conjugated increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hepatitis (fatal outcome has been very exceptional).</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>Rash in particular maculo-papular</p></td><td style="vertical-align:top"><p>Angioedema; very exceptionally, the airway obstruction resulting from angioedema may have a fatal outcome; pruritus, hyperhidrosis</p></td><td style="vertical-align:top"><p>Exfoliative dermatitis, urticaria, onycholysis</p></td><td style="vertical-align:top"><p>Photosensitiv ity reaction</p></td><td style="vertical-align:top"><p>Toxic epidermal necrolysis, Stevens- Johnson syndrome, erythema multiforme, pemphigus, psoriasis aggravated, dermatitis psoriasiform, pemphigoid or lichenoid exanthema or enanthema, alopecia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>Muscle spasms, myalgia</p></td><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Renal impairment including renal failure acute, urine output increased, worsening of a pre-existing proteinuria, blood urea increased, blood creatinine increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Transient erectile impotence, libido decreased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Gynaecomasti a</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>Chest pain, fatigue</p></td><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The safety of ramipril was monitored in 325 children and adolescents, aged 2-16 years old during</p><p>2 clinical trials. Whilst the nature and severity of the adverse events are similar to that of the adults, the frequency of the following is higher in the children:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tachycardia, nasal congestion and rhinitis, &quot;common&quot; (i.e., &ge; 1/100 to &lt; 1/10) in paediatric, and &quot;uncommon&quot; (i.e. &ge; 1/1,000 to &lt; 1/100) in adult population.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Conjunctivitis &quot;common&quot; (i.e., &ge; 1/100 to &lt; 1/10) in paediatric and &quot;rare&rdquo; (i.e. &ge; 1/10,000 to &lt; 1/1,000) in adult population.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tremor and urticaria &quot;uncommon&quot; (i.e. &ge; 1/1,000 to &lt; 1/100) in paediatric population and &quot;rare&quot; (i.e. &ge; 1/10,000 to &lt; 1/1,000) in adult population.</p><p>&nbsp;</p><p>The overall safety profile for ramipril in paediatric patients does not differ significantly from the safety profile in adults.</p><p>&nbsp;</p><p>To report any side effect(s):<br />&bull;Saudi Arabia:<br />-National Pharmacovigilance Center (NPC):&bull;Toll free phone: 19999&bull;Fax: +966-11-205-7662&bull;E-mail: npc.drug@sfda.gov.sa&bull;Website: www.ade.sfda.gov.sa<br />&bull;Other GCC states:<br />-Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms</p><p>&nbsp;</p><p>Symptoms associated with overdose of ACE inhibitors may include excessive peripheral vasodilatation (with marked hypotension, shock), bradycardia, electrolyte disturbances, and renal failure.</p><p>&nbsp;</p><p>Management</p><p>&nbsp;</p><p>The patient should be closely monitored and the treatment should be symptomatic and supportive. Suggested measures include primary detoxification (gastric lavage, administration of adsorbents) and measures to restore haemodynamic stability, including, administration of alpha 1 adrenergic agonists or angiotensin II (angiotensinamide) administration. Ramiprilat, the active metabolite of ramipril is poorly removed from the general circulation by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Agents acting on the renin-angiotensin system, ACE inhibitors, plain, ATC code: C09AA05</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Ramiprilat, the active metabolite of the prodrug ramipril, inhibits the enzyme dipeptidylcarboxypeptidase I (synonyms: angiotensin-converting enzyme; kininase II). In plasma and tissue this enzyme catalyses the conversion of angiotensin I to the active vasoconstrictor substance</p><p>&nbsp;</p><p>angiotensin II, as well as the breakdown of the active vasodilator bradykinin. Reduced angiotensin II formation and inhibition of bradykinin breakdown lead to vasodilatation.</p><p>&nbsp;</p><p>Since angiotensin II also stimulates the release of aldosterone, ramiprilat causes a reduction in aldosterone secretion. The average response to ACE inhibitor monotherapy was lower in black (Afro- Caribbean) hypertensive patients (usually a low-renin hypertensive population) than in non-black patients.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p>Antihypertensive properties:</p><p>Administration of ramipril causes a marked reduction in peripheral arterial resistance. Generally, there are no major changes in renal plasma flow and glomerular filtration rate. Administration of ramipril to patients with hypertension leads to a reduction in supine and standing blood pressure without a compensatory rise in heart rate.</p><p>In most patients the onset of the antihypertensive effect of a single dose becomes apparent 1 to 2 hours after oral administration. The peak effect of a single dose is usually reached 3 to 6 hours after oral administration. The antihypertensive effect of a single dose usually lasts for 24 hours.</p><p>The maximum antihypertensive effect of continued treatment with ramipril is generally apparent after 3 to 4 weeks. It has been shown that the antihypertensive effect is sustained under long term therapy lasting 2 years.</p><p>Abrupt discontinuation of ramipril does not produce a rapid and excessive rebound increase in blood pressure.</p><p>&nbsp;</p><p>Heart failure:</p><p>In addition to conventional therapy with diuretics and optional cardiac glycosides, ramipril has been shown to be effective in patients with functional classes II-IV of the New-York Heart Association. The medicinal product had beneficial effects on cardiac haemodynamics (decreased left and right ventricular filling pressures, reduced total peripheral vascular resistance, increased cardiac output and improved cardiac index). It also reduced neuroendocrine activation.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p><u>Cardiovascular prevention/Nephroprotection;</u></p><p>&nbsp;</p><p>A preventive placebo-controlled study (the HOPE-study), was carried out in which ramipril was added to standard therapy in more than 9,200 patients. Patients with increased risk of cardiovascular disease following either atherothrombotic cardiovascular disease (history of coronary heart disease, stroke or peripheral vascular disease) or diabetes mellitus with at least one additional risk factor (documented microalbuminuria, hypertension, elevated total cholesterol level, low high-density lipoprotein cholesterol level or cigarette smoking) were included in the study.</p><p>&nbsp;</p><p>The study showed that ramipril statistically significantly decreases the incidence of myocardial infarction, death from cardiovascular causes and stroke, alone and combined (primary combined events).</p><p>The HOPE study: Main results</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Ramipril</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>relative risk (95% confidence interval)</strong></p></td><td style="vertical-align:top"><p><strong>p-value</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>%</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>All patients</strong></p></td><td style="vertical-align:top"><p><strong>n=4,645</strong></p></td><td style="vertical-align:top"><p><strong>n=4,652</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Primary combined events</strong></p></td><td style="vertical-align:top"><p><strong>14.0</strong></p></td><td style="vertical-align:top"><p><strong>17.8</strong></p></td><td style="vertical-align:top"><p><strong>0.78 (0.70-0.86)</strong></p></td><td style="vertical-align:top"><p><strong>&lt;0.001</strong></p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Myocardial infarction</p></td><td style="vertical-align:top"><p>9.9</p></td><td style="vertical-align:top"><p>12.3</p></td><td style="vertical-align:top"><p>0.80 (0.70-0.90)</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p>Death from cardiovascular causes</p></td><td style="vertical-align:top"><p>6.1</p></td><td style="vertical-align:top"><p>8.1</p></td><td style="vertical-align:top"><p>0.74 (0.64-0.87)</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p>Stroke</p></td><td style="vertical-align:top"><p>3.4</p></td><td style="vertical-align:top"><p>4.9</p></td><td style="vertical-align:top"><p>0.68 (0.56-0.84)</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Secondary endpoints</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Death from any cause</p></td><td style="vertical-align:top"><p>10.4</p></td><td style="vertical-align:top"><p>12.2</p></td><td style="vertical-align:top"><p>0.84 (0.75-0.95)</p></td><td style="vertical-align:top"><p>0.005</p></td></tr><tr><td style="vertical-align:top"><p>Need for Revascularisation</p></td><td style="vertical-align:top"><p>16.0</p></td><td style="vertical-align:top"><p>18.3</p></td><td style="vertical-align:top"><p>0.85 (0.77-0.94)</p></td><td style="vertical-align:top"><p>0.002</p></td></tr><tr><td style="vertical-align:top"><p>Hospitalisation for unstable angina</p></td><td style="vertical-align:top"><p>12.1</p></td><td style="vertical-align:top"><p>12.3</p></td><td style="vertical-align:top"><p>0.98 (0.87-1.10)</p></td><td style="vertical-align:top"><p>NS</p></td></tr><tr><td style="vertical-align:top"><p>Hospitalisation for heart failure</p></td><td style="vertical-align:top"><p>3.2</p></td><td style="vertical-align:top"><p>3.5</p></td><td style="vertical-align:top"><p>0.88 (0.70-1.10)</p></td><td style="vertical-align:top"><p>0.25</p></td></tr><tr><td style="vertical-align:top"><p>Complications related to diabetes</p></td><td style="vertical-align:top"><p>6.4</p></td><td style="vertical-align:top"><p>7.6</p></td><td style="vertical-align:top"><p>0.84 (0.72-0.98)</p></td><td style="vertical-align:top"><p>0.03</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>The MICRO-HOPE study, a predefined substudy from HOPE, investigated the effect of the addition of ramipril 10 mg to the current medical regimen versus placebo in 3,577 patients at least &ge; 55 years old (with no upper limit of age), with a majority of type 2 diabetes (and at least another CV risk factor), normotensive or hypertensive.</p><p>&nbsp;</p><p>The primary analysis showed that 117 (6.5 %) participants on ramipril and 149 (8.4 %) on placebo developed overt nephropathy, which corresponds to a RRR 24 %; 95 % CI [3-40], p = 0.027.</p><p>&nbsp;</p><p>The REIN study, a multicenter randomized, double-blind parallel group, placebo-controlled study aimed at assessing the effect of treatment with ramipril on the rate of decline of glomerular function rate (GFR) in 352 normotensive or hypertensive patients (18-70 years old) suffering from mild (i.e. mean urinary protein excretion &gt; 1 and &lt; 3 g/24 h) or severe proteinuria (&ge; 3 g/24 h) due to chronic non-diabetic nephropathy. Both subpopulations were prospectively stratified.</p><p>&nbsp;</p><p>The main analysis of patients with the most severe proteinuria (stratum prematurely disrupted due to benefit in ramipril group) showed that the mean rate of GFR decline per month was lower with ramipril than with placebo; -0.54 (0.66) vs. -0.88 (1.03) ml/min/month, p = 0.038. The intergroup difference was thus 0.34 [0.03-0.65] per month, and around 4 ml/min/year; 23.1 % of the patients in the ramipril group reached the combined secondary endpoint of doubling of baseline serum creatinine concentration and/or end-stage renal disease (ESRD) (need for dialysis or renal transplantation) vs.</p><p>45.5 % in the placebo group (p = 0.02).</p><p>&nbsp;</p><p><u>Dual blockade of the renin-angiotensin-aldosterone system (RAAS)</u></p><p>&nbsp;</p><p>Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker.</p><p>ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON- D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.</p><p>These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.</p><p>&nbsp;</p><p>ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.</p><p>ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</p><p>&nbsp;</p><p><u>Secondary prevention after acute myocardial infarction</u></p><p>&nbsp;</p><p>The AIRE study included more than 2,000 patients with transient/persistent clinical signs of heart failure after documented myocardial infarction. The ramipril treatment was started 3 to 10 days after the acute myocardial infarction. The study showed that after an average follow-up time of 15 months the mortality in ramipril-treated patients was 16.9 % and in the placebo treated patients was 22.6 %. This means an absolute mortality reduction of 5.7 % and a relative risk reduction of 27 % (95 % CI [11-40 %]).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>In a randomized, double-blind, placebo-controlled clinical study involving 244 paediatric patients with hypertension (73% primary hypertension), aged 6-16 years, patients received either low dose, medium dose or high dose of ramipril to achieve plasma concentrations of ramiprilat corresponding to the adult dose range of 1.25 mg, 5 mg and 20 mg on the basis of body weight. At the end of 4 weeks, ramipril was ineffective in the endpoint of lowering systolic blood pressure but lowered diastolic blood pressure at the highest dose. Both medium and high doses of ramipril showed significant reduction of both systolic and diastolic blood pressure in children with confirmed hypertension.</p><p>&nbsp;</p><p>This effect was not seen in a 4 week dose-escalation, randomized, double-blind withdrawal study in 218 paediatric patients aged 6-16 years (75% primary hypertension), where both diastolic and systolic blood pressures demonstrated a modest rebound but not a statistically significant return to the baseline, in all three dose levels tested [low dose (0.625 mg &ndash; 2.5 mg), medium dose (2.5 mg &ndash; 10 mg) or high dose (5mg &ndash; 20 mg)] ramipril based on weight. Ramipril did not have a linear dose response in the paediatric population studied.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Following oral administration ramipril is rapidly absorbed from the gastrointestinal tract: peak plasma concentrations of ramipril are reached within one hour. Based on urinary recovery, the extent of absorption is at least 56 % and is not significantly influenced by the presence of food in the gastrointestinal tract. The bioavailability of the active metabolite ramipril at after oral administration of 2.5 mg and 5 mg ramipril is 45 %.</p><p>Peak plasma concentrations of ramiprilat, the sole active metabolite of ramipril are reached 2-4 hours after ramipril intake. Steady state plasma concentrations of ramiprilat after once daily dosing with the usual doses of ramipril are reached by about the fourth day of treatment.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>The serum protein binding of ramipril is about 73 % and that of ramipril at about 56 %.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Ramipril is almost completely metabolised to ramiprilat, and to the diketopiperazine ester, the diketopiperazine acid, and the glucuronides of ramipril and ramiprilat.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Excretion of the metabolites is primarily renal.</p><p>Plasma concentrations of ramiprilat decline in a polyphasic manner. Because of its potent, saturable binding to ACE and slow dissociation from the enzyme, ramiprilat shows a prolonged terminal elimination phase at very low plasma concentrations.</p><p>After multiple once-daily doses of ramipril, the effective half-life of ramiprilat concentrations was 13- 17 hours for the 5-10 mg doses and longer for the lower 1.25-2.5 mg doses. This difference is related to the saturable capacity of the enzyme to bind ramiprilat.</p><p>&nbsp;</p><p><em>Lactation</em></p><p>A single oral dose of ramipril produced an undetectable level of ramipril and its metabolite in breast milk. However the effect of multiple doses is not known.</p><p>&nbsp;</p><p>Patients with renal impairment (see section 4.2)</p><p>Renal excretion of ramiprilat is reduced in patients with impaired renal function, and renal ramiprilat clearance is proportionally related to creatinine clearance. This results in elevated plasma concentrations of ramiprilat, which decrease more slowly than in subjects with normal renal function.</p><p>&nbsp;</p><p>Patients with hepatic impairment (see section 4.2)</p><p>In patients with impaired liver function, the metabolism of ramipril to ramiprilat was delayed, due to diminished activity of hepatic esterases, and plasma ramipril levels in these patients were increased. Peak concentrations of ramiprilat in these patients, however, are not different from those seen in subjects with normal hepatic function.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The pharmacokinetic profile of ramipril was studied in 30 paediatric hypertensive patients, aged 2-16 years, weighing &gt;10 kg. After doses of 0.05 to 0.2 mg/kg, ramipril was rapidly and extensively metabolized to ramiprilat. Peak plasma concentrations of ramiprilat occurred within 2-3 hours.</p><p>Ramiprilat clearance highly correlated with the log of body weight (p&lt;0.01) as well as dose (p&lt;0.001). Clearance and volume of distribution increased with increasing children age for each dose group.</p><p>The dose of 0.05 mg /kg in children achieved exposure levels comparable to those in adults treated with ramipril 5mg. The dose of 0.2 mg/kg in children resulted in exposure levels higher than the maximum recommended dose of 10 mg per day in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Oral administration of ramipril has been found to be devoid of acute toxicity in rodents and dogs. Studies involving chronic oral administration have been conducted in rats, dogs and monkeys.</p><p>Indications of plasma electrolyte shifts and changes in blood picture have been found in the 3 species. As an expression of the pharmacodynamic activity of ramipril, pronounced enlargement of the juxtaglomerular apparatus has been noted in the dog and monkey from daily doses of 250 mg/kg/d.</p><p>Rats, dogs and monkeys tolerated daily doses of 2, 2.5 and 8 mg/kg/d respectively without harmful effects. Irreversible kidney damage has been observed in very young rats given a single dose of ramipril. Reproduction toxicology studies in the rat, rabbit and monkey did not disclose any teratogenic properties.</p><p>Fertility was not impaired either in male or in female rats.</p><p>The administration of ramipril to female rats during the foetal period and lactation produced irreversible renal damage (dilatation of the renal pelvis) in the offspring at daily doses of 50 mg/kg body weight or higher.</p><p>Extensive mutagenicity testing using several test systems has yielded no indication that ramipril possesses mutagenic or genotoxic properties.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypromellose</p><p>Cellulose,</p><p>microcrystalline Starch,</p><p>pregelatinised (maize)</p><p>Sodium hydrogen carbonate</p><p>Sodium stearyl fumarate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30 &deg;C.</p><p>Store in the original package.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The tablets are packed in aluminium/aluminium blisters and inserted in a carton or are packed in HDPE bottle with screw cap filled with silica gel as desiccant.</p><p>&nbsp;</p><p>Pack sizes:</p><p>Blisters: 14, 20, 28, 30, 50, 60, 98, 100, 250 tablets Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hexal AG Industriestr. 25
D-83607 Holzkirchen Germany

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                06/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>